Zenarestat

This classification denotes an aldose reductase inhibitor with the molecular formula C17H11BrClFN2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 180C9PJ8JT, chemically known as 3-(4-bromo-2-fluorobenzyl)-7-chloro-3,4-dihydro-2,4-dioxo-1(2h)-quinazolineacetic acid but generally known as zenarestat, which bears US NIH Compound Identifier 5724. European Medicines Agency schedules Zenarestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00145MIG. The term ZENARESTAT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). ZENARESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule zenarestat under HS 29335995 and SITC 51576. As of Q4 2014, ZENARESTAT remains the US FDA Preferred Term for this commodity. Zenarestat bears US NLM identifiers UMLS ID C0149322 and NCI Concept Code C72879. SMILES: BRC1CC(F)C(CN2C(=O)N(C3C(C2=O)CCC(CL)C3)CC(=O)O)CC1.